Introduction

I
n the Netherlands, 26% of the population are expected to be above 65 years of age by 2040. 1 This reflects a trend throughout Europe. 2 This large group of elderly people stands a risk of developing multi-morbidity, 3, 4 which is associated with increased disability and higher mortality. 5, 6 Because of this, the use of multiple medication regimens, known as polypharmacy, is common. [7] [8] [9] [10] In the Netherlands, it has been estimated that polypharmacy-that is the chronic use of five or more medication regimens-occurs in 44% of the elderly (!65 year). 11 Polypharmacy is associated with an increased risk of adverse drug events. The elderly are particularly at risk, as polypharmacy increases the risk of geriatric syndromes such as cognitive impairment, urinary incontinence and falls, leading to hospital admissions. 8, 12, 13 It has been reported that 12% of the hospital admissions amongst older patients are due to adverse drug events. 8 However, polypharmacy can be beneficial if the medication is appropriately prescribed, which means by taking into account the patient's history and all the medicines taken.
14 However, this is a complex task due to factors such as age-related changes in body composition and multiple pathologies which involve different healthcare professionals. 7 It requires clinical knowledge about the effect of medicines and collaboration between the healthcare professionals. 15 Different interventions have been developed to improve medication safety for the elderly with polypharmacy. 7 A medication review, entailing a multidisciplinary and structured examination of the medicines, is often suggested. 7, [16] [17] [18] [19] In the Netherlands, the Multidisciplinary Guideline 'Polypharmacy amongst the Elderly' (MDG Polypharmacy) 15 was drawn up in 2012 and recommends that healthcare professionals and patients review the medication together, using the Systematic Tool to Reduce Inappropriate Prescribing (STRIP). The STRIP contains five steps: (i) taking the pharmacotherapeutic medical history; (ii) analysing it; (iii) consultation between the physician and pharmacist, in drawing up a pharmacotherapeutic treatment plan; (iv) consultation with the patient, in establishing this treatment plan and (v) follow-up and monitoring (Supplementary Appendix S1). Patients are eligible for a medication review if they are older than 65 years of age, are chronic users of five or more medications at level 3 of the Anatomical Therapeutic Chemical classification system and have one or more of the following risk factors: a decline in renal function; a cognition decline; a risk of falling, a decline in compliance; are not living independently and undergo an unplanned hospital admission.
The development and implementation of this guideline is initiated by the branch organisations of general practitioners (GPs), geriatricians and other medical specialists by means of publishing the guideline in medical magazines and by providing training initiatives. One essential step towards implementing a guideline successfully is to gain insight into the discrepancy between current practice and the best practice described in the guideline. 20, 21 Information about this discrepancy can give a sense of urgency and can motivate healthcare professionals to change their behaviour. 20 This contribution aims to provide insight into the current practice within Dutch pharmacotherapeutic care for the elderly with polypharmacy. The first objective is to examine to what extent the current practice mirrors the best practice described in the MDG Polypharmacy. The second objective is to examine which barriers are present which threaten pharmacotherapeutic care.
Methods
Design and setting
An observational study was conducted in 2013/14, using a questionnaire distributed amongst elderly patients with polypharmacy and healthcare professionals involved in pharmacotherapeutic care. The latter can be classified into the following healthcare domains: GPs and community pharmacists (primary care), hospital physicians called medical specialists in the Netherlands, hospital pharmacists, elderly care physicians working in nursing homes and psychiatrists (secondary care).
Participants
We aimed to include 100 participants per domain, choosing to select the participants geographically around the community pharmacists as they play a central role in the pharmacotherapeutic care. From the total pool of Dutch community pharmacists (1970), a random sample of 150 was invited to participate. To represent a realistic care network around elderly patients, twenty community pharmacists were selected at random and were, in turn, asked to invite randomly, using their information system, ten elderly patients with polypharmacy (!65 year and !5 medicines). We sampled, at random, five GPs, five medical specialists, five elderly care physicians and five psychiatrists in the regions where those twenty community pharmacists work, using the national medical address book. Additional samples needed to be drawn to maximise the response. From each hospital in the Netherlands, the hospital pharmacist with whose name the pharmacist was registered was invited to participate. A digital questionnaire was sent to the healthcare professionals, a written questionnaire was sent to the patients. Non-responders were phoned, until reached, for a reminder.
Questionnaire
The patients' questionnaire contained the following sections: personal information; use of medication; the patient's experience of the pharmacotherapeutic care; and their judgement about the quality of their care. Informed consent was obtained by asking the patients to sign a form after they were verbally and written informed by the community pharmacist. The questionnaire for the healthcare professionals contained the following sections: personal and organisational information; current pharmacotherapeutic practice; and the presence of barriers. For most questions a five point Likert scale was used. The questionnaires were tested in all healthcare domains and in the patient's domain. Those carrying out the tests filled in the questionnaire and their comments were discussed with the researchers. Questionnaires differed slightly per healthcare domain as some questions were not always applicable.
To assess current pharmacotherapeutic practice, we developed questions about the experiences with the patient group; the use of the MDG Polypharmacy including opinions about its use; factors which promote its use; and, the number of patients that would fit the criteria of a medication review.
The barriers to best practice in pharmacotherapeutic care were first identified by reviewing the literature. A search was conducted for articles in Medline and the Cochrane database using search terms based on those used in a review of risks to elderly patients with polypharmacy 22 (Supplementary Appendix S2). Relevant references in the resulting articles were also included. An expert panel, purposively sampled from the personal network of the researchers, carried out a prioritisation in order to limit the questions to the most important barriers. The inclusion criteria were: expertise in the care of polypharmacy; working in the field and representing one of the healthcare domains we included in this study. The expert group consisted of three community pharmacists, one GP, two medical specialists, one elderly care physician, one hospital pharmacist and one psychiatrist. The following barriers were selected as the most important and were adopted for use in the questionnaire as follows:
(i) Inadequate transfer of patient records: asking whether the information system is linked with that of other healthcare professionals for the purpose of an adequate transfer of patient records.
(ii) Insufficient documentation of the prescribed drugs: asking whether the information in the patient records is sufficient to give adequate pharmacotherapeutic care. (iii) A lack of collaboration between professionals: asking how the healthcare professionals judge in general the availability of the other healthcare professionals. (iv) A failure to take a full control of the medication: asking whether, and if so, which healthcare provider is in control of the medication in four different scenarios: a patient living at home, being hospitalised, being admitted to a nursery home, or being under the treatment of a psychiatrist. (v) Insufficient involvement of the patient in the pharmacotherapeutic care process: asking how often step one and four of the STRIP is performed as those steps involve consultation with the patient. Furthermore, there were questions about the patient's involvement in the patient's questionnaire.
The data were stored in a secured environment without direct traceable personal data. The differences between the healthcare domains demonstrated by the Likert scale questions were tested using a one-way ANOVA test. When more than two domains were compared a Bonferroni post hoc test was conducted to test the differences between all the pairs of domains. For categorical questions a Pearson 2 test was conducted to assess the association between the question and the domains.
This study was conducted within the Academic Collaborative Centre on Supervision. Here, four different research institutions work together with the Dutch Healthcare Inspectorate (IGZ; Supplementary Appendix S3) in order to develop evidence-based supervision. This research is carried out by the EMGO + Institute/ VU University Medical Center in collaboration with the IGZ. To prevent information bias the IGZ was not explicitly mentioned when approaching participants. The study was approved by the Medical Ethical Committee of the VU University Medical Center in July 2013.They established this study did not fall under the scope of the Medical Research Involving Human Subjects Acts. The protocol is in accordance with Dutch privacy regulations. Table 1 demonstrates the answers given by the healthcare professionals to the questions about current pharmacotherapeutic practice. In all healthcare domains, the professionals scored, on average, three or higher when asked to what extent they experienced care for the elderly with polypharmacy as a problem in their population. Around half of the community pharmacists (54.2%) and the GPs (45.2%) were convinced about the use of the MDG Polypharmacy (scored 4 of above). However, only 26% of the community pharmacists and 6.5% of the GPs use the guideline often to always. Furthermore, only 14% of the medical specialists, 20% of the elderly care physicians and 24% of the hospital pharmacists implemented the guideline.
Results
Step one of the STRIP was mostly conducted by the psychiatrist and the community pharmacist (respectively 50% and 45% scored 4 or above)) and step four of the STRIP was mostly done by the community pharmacist (47% scored 4 or above)). Considering all the pre-conditions needed to implement the guideline, financial support was seen as the most important for promoting its use by the community pharmacists and GPs (mean score of 4.1 and 3.7 respectively). Reimbursement for training and whether or not a specialised professional performed the medication reviews were seen as less important. Table 2 demonstrates the results of the healthcare professionals on the questions about the presence of barriers. Inadequate transfer of patient records (i): most of the healthcare professionals were linked to another system; 84% of the community pharmacists were linked to a regional system and 73% of the GPs were linked to GPs in their region. Seventy-one percent of the psychiatrists said that they had no links. Insufficient documentation of the prescribed drugs in the patient record (ii): both pharmacists working in a hospital and the community had the lowest average score on the question of whether the information in the patient records is sufficient to give adequate pharmacotherapeutic care (2.7 and 2.8 respectively). A lack of collaboration between healthcare professionals (iii): the community pharmacists judged the availability of other community pharmacists and the GP better than healthcare professionals in secondary care (4.3/4.2 for, respectively, the community pharmacist and the GP, versus 2.9 and 2.7 respectively for the medical specialist and the psychiatrist). A failure to take a full control of the medication (iv): most of the healthcare professionals indicated that the main prescriber in the scenario is in control of the medication (% in bold). Twenty-three healthcare professionals (7.5%) mentioned that this question was difficult to answer as the person in control is dependent upon the particular situation. Twenty-one healthcare professionals (6.9%) explained that the control is shared with other healthcare professionals, often the pharmacist (n = 21). Table 3 demonstrates the results of the patients' questionnaire. Only a few patients mentioned that they had experienced problems in the care surrounding their medications (7.3%). One third of the patients mentioned that their medication was thoroughly assessed last year and this assessment was done by the GP (55%), medical specialist (41%) and the community pharmacist (28%).
Discussion
Most healthcare professionals acknowledge that polypharmacy poses a threat to the quality of pharmacotherapeutic care. The MDG Polypharmacy is seen as a possible solution; however, most professionals did not actually use the guideline.
The lack of implementation can be, in part, explained by the large number of patients eligible for a medication review, combined with the time needed to conduct a proper review. For instance, the community pharmacist had, on average, 470 elderly patients with polypharmacy. When this number is multiplied with around 2 h per review, this results in 940 h needed to conduct medication reviews that have to be slotted in alongside normal work activities. In this way there is simply not enough capacity to provide all patients with an extensive medication review. There are several solutions to overcome this problem. Firstly, the capacity of competent staff can be increased. This requires proper reimbursement, a pre-condition mentioned by the GP and the community pharmacist as most needed in order to implement the guideline. Secondly, the selection of patients for a medication review could be sharpened, to ensure that at least the high-risk patients receive the review. Thirdly, the review will be more efficient when the method can be tailor made, so it can be more in line with the complexity of the individual patient. We believe it is significant that the large number of patients, and the insufficient reimbursement for healthcare professionals, were also mentioned in a Dutch report about the risks in care for the elderly with polypharmacy. 22 Five barriers hampering the implementation of the best care were highlighted by the experts. The presence of these barriers was confirmed in part in our study.
The barrier inadequate transfer of patient records, taken account of in the questionnaire by asking about the links between information systems, was partly confirmed. Our results demonstrate that many healthcare professionals do have links with the information systems of other healthcare professionals, but mainly within their own domain of primary or secondary care. This trend was also seen when asking about the barrier, a lack of collaboration between professionals: healthcare professionals can reach each other more easily if they work within the same domain of primary or secondary care than if they do not. This gap between domains is a recognised problem, 23, 24 as elderly patients often move from primary to 
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Insufficient documentation of the prescribed drugs was partly present in current practice. Most healthcare professionals were reasonably satisfied in their judgment about the quality of information although the community-and hospital pharmacists scored lower than the other healthcare professionals. This is worrying, as the pharmacists play an important role in preventing adverse drug events. 27 The barrier, a failure to take a full control of the medication was not entirely confirmed. Only a small group of respondents indicated that nobody has the control of the medication, so in most situations there is a healthcare professional in control. Some healthcare professionals explained that the control is often a collaboration between healthcare professionals or is dependent upon the individual situation of a patient. Whether this control was sufficient could not be answered correctly from the results.
The barrier insufficient involvement of the patient is partly confirmed by the healthcare professionals, as step one and four of the STRIP is not always performed. However, this barrier is not confirmed by the patients. Most patients were involved when their medication was thoroughly assessed and most were satisfied with the care they received. It should be kept in mind that age is a wellknown determinant of patient satisfaction; older patients in general score well and are more satisfied than younger patients. 28, 29 No studies were found in the international literature which measure the implementation rate of a guideline such as the MDG Polypharmacy. Studies were found which acknowledged that the implementation of such evidence-based guidelines is challenging and requires significant facilitation, such as proper training. [30] [31] [32] In particular, we found a tailored workshop in Germany aimed at implementing guideline recommendations for polypharmacy into practice together with consideration of the barriers of this. From the results of this study, it appears that such a workshop is appropriate to impart knowledge about medication management to participants in that country. 31 It seems that the MDG guideline does not perfectly fit the daily reality of healthcare professionals. Therefore, such a workshop could help to improve the implementation of the MDG Polypharmacy.
Limitations
This baseline measurement took place two years after the introduction of the MDG Polypharmacy. As stated in the literature, 20, 21, [30] [31] [32] introducing guidelines into daily practice is challenging. More time and effort may be needed to align current practice with best practice. However, current implementation should still benefit from the results of the present study.
The response remained low, in spite of efforts to increase it. A lack of time was the main reason for not participating. The low response could have resulted in an overestimation of compliance with the MDG guideline, as those who responded probably consider this an important issue and therefore made the time to respond. However, we don't expect this materially influenced our conclusion. The data seem to be representative of the Dutch situation. The respondents were widely spread around the country, there was a variance between 3) The judgment of the patient about the quality of the medication record of the GP Mean (SD) (1 = 'bad'; 5 = 'excellent') Number of patients indicating that the adjustments made followed by the medication review were evaluated or an evaluation is planned, step five of the STRIP (%) the results and the results fit in with the expectations of the expert panel. The difference between the positive results of the patients and the relatively negative results of the healthcare professionals, could be caused by response bias or the method of the written questionnaire, which could be inappropriate for the patiënt group. Further research is needed.
Conclusion
There is an awareness amongst healthcare professionals of the problems in current pharmacotherapeutic care for the elderly with polypharmacy. There is a will to improve through following the MDG Polypharmacy; however, the presence of barriers hampers the implementation of this guideline. Good management of those barriers is necessary: improve the collaboration between primary and secondary care, for example, by starting with local agreements on the roles and responsibilities in pharmacotherapeutic care, and enhance the documentation of prescribed drugs. Furthermore, the recommendations in the guideline should connect in a better manner to the real situation healthcare professionals work in so it might fit better into the existing resources. For example, by providing a selection of high-risk patients who at least need a medication review or by providing a tailored workshop in which healthcare professionals are advised how to implement the recommendations with consideration of the barriers.
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